logo

Cyclo Therapeutics, Inc. (CYTH)



Trade CYTH now with
  Date
  Headline
10/18/2021 8:09:56 AM Cyclo Therapeutics Announces Abstract Accepted For Poster Presentation
8/17/2021 8:16:30 AM Cyclo Therapeutics Q2 Net Loss $3.6 Mln Or $0.56/shr Vs. Loss $2.19 Mln Or $1.61/shr Prior Year
6/17/2021 8:13:04 AM Cyclo Therapeutics Commences Patient Enrollment In Phase 3 Study Of Trappsol Cyclo In Niemann-Pick Type C1
5/11/2021 9:07:55 AM Cyclo Therapeutics Names Lori McKenna Gorski Global Head Of Patient Advocacy
4/20/2021 9:28:31 AM Cyclo Gets FDA Feedback Supporting Development Strategy To Submit IND Application For Phase 2 Study Of Trappsol Cyclo
3/25/2021 8:39:24 AM Cyclo Therapeutics Meets Primary Efficacy Endpoint In Phase 1/2 Trial From Intravenous Trappsol Cyclo
3/10/2021 8:36:38 AM Cyclo Therapeutics Names Russ Belden Acting Chief Commercial Officer
3/9/2021 9:09:39 AM Cyclo Gets Positive Opinion From Paediatric Committee Of EMA On Agreement Of PIP For Trappsol Cyclo
3/4/2021 9:14:07 AM Cyclo Therapeutics Says Last Patient Completed Their Last Visit In The Phase 1/2 Study Evaluating Trappsol
2/9/2021 8:09:00 AM Cyclo Therapeutics Presents Positive Data From Clinical Development Program For Trappsol Cyclo At WORLDSymposium 2021